Antisense phosphorothioates as antivirals against human immunodeficiency virus (HIV) and hepatitis B virus (HBV).
For the past 10 years we have focused on the development of antisense treatments against viral infections such as human immunodeficiency virus (HIV) and hepatitis B virus (HBV). We have demonstrated that phosphorothioate oligomers have in vitro anti-HIV activities and in vivo anti-HBV activity. In vitro anti-HIV activities of phosphorothioate oligodeoxynucleotides (S-oligo) were classified into sequence non-specific (non-antisense) and sequence specific (antisense). We found that toxicity of S-oligo could be also classified into the same 2 categories. Since some of non-specific toxicity is dependent on experimental conditions, in each experiment, we should pay attention to minimize non-specific toxicity of the oligomers.
Matsukura
M
M
Department of Child Development, Kumamoto University School of Medicine, Japan.
Koike
K
K
Zon
G
G
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D015967:Gene Expression Regulation, Viral / Q000187:drug effects; D006678:HIV / Q000187:drug effects*; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*
D000998:Antiviral Agents; D016376:Oligonucleotides, Antisense